Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer’s Palbociclib (PD-0332991) Receives FDA Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
Pfizer’s Palbociclib (PD-0332991) Receives FDA Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
Pfizer’s Palbociclib (PD-0332991) Receives FDA Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
Submitted by
admin
on April 10, 2013 - 11:10am
Source:
Yahoo
News Tags:
Pfizer
palbociclib
FDA
breast cancer
Headline:
Pfizer’s Palbociclib (PD-0332991) Receives FDA Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
Do Not Allow Advertisers to Use My Personal information
